The beat-and-raise quarter with improving margins and strong Cigna Healthcare performance supports a bullish read-through. Monitor the Pharmacy Benefit Services margin trajectory and the impact of expected client transitions on Evernorth's profitability. The raised guidance (+$0.10) is modest but signals confidence in the diversified portfolio.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 30 $290.33entry
- T+1 · 7mo ago −2.79%α −3.01% · $282.24
- T+5 · 6mo ago −2.30%α −4.03% · $283.65
- T+20 · 6mo ago −4.50%α −9.73% · $277.25
- T+60 · 4mo ago −0.26%α −3.08% · $289.57
Price Chart
How similar events traded
Executive Summary
Cigna Group reported strong Q1 2026 results with adjusted EPS of $7.79, beating the $7.62 consensus by 2.2%, and total revenue of $68.5B (+5% YoY). The company raised its full-year 2026 adjusted EPS outlook to at least $30.35 (from at least $30.25), driven by strong performance in Cigna Healthcare (pre-tax income +18% YoY) and improved operating efficiency, partially offset by a 28% decline in Pharmacy Benefit Services operating income.
Key Financial Metrics
Key Facts
- Q1 2026 adjusted EPS $7.79 vs consensus $7.62 (beat by 2.2%)
- Q1 2026 total revenue $68.5B, +5% YoY
- Full-year 2026 adjusted EPS guidance raised to at least $30.35 (from at least $30.25)
- Cigna Healthcare pre-tax adjusted income +18% YoY to $1.514B
- Cigna Healthcare MCR improved to 79.8% from 82.2% YoY
- Evernorth Health Services adjusted revenue +9% YoY, but pre-tax income only +2%
- Pharmacy Benefit Services pre-tax income -28% YoY due to lower contributions from large clients
- SG&A expense ratio improved to 5.4% from 6.4% YoY (adjusted 4.8% from 5.8%)
- Debt-to-capitalization ratio improved to 42.3% from 43.0% at year-end 2025
- Total medical customers increased 1% from Dec 2025 to 18.3M
Financial Impact
Q1 2026 adjusted EPS $7.79 vs $7.62 consensus; revenue $68.5B vs $66.2B consensus; guidance raised by $0.10 to at least $30.35
Risk Factors
- Pharmacy Benefit Services pre-tax income declined 28% YoY, indicating competitive pressure in PBM
- Total pharmacy customers decreased 2% from Dec 2025, reflecting expected client transitions
- Cigna Healthcare adjusted revenue declined 21% YoY (though +8% ex-HCSC divestiture)
- Full-year guidance raise of only $0.10 suggests limited upside conviction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-017971 |
| Document: ef20071317_8k.htm | 0001140361-26-017971 |
| Document: 0001140361-26-017971-index-headers.html | 0001140361-26-017971 |
| Document: 0001140361-26-017971-index.html | 0001140361-26-017971 |
| Document: 0001140361-26-017971.txt | 0001140361-26-017971 |
| 8-K Data (Synthetic) | 0001140361-26-017971 |
Track record
16 reports on CI
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $301.48 to $296.27 Now $297.00 −1.49% ▼ −1.73% −5.02% vs SPY
- Oct 28, 202619d ago Press Release Neutral 2/10 Entry $298.41 to $301.48 Now $297.00 −0.47% ▲ +1.03% +5.75% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $295.00 to $305.41 Now $297.00 +0.68% ▲ +3.53% +4.24% vs SPY
- Oct 20, 202627d ago Institutional Cluster Neutral 3/10 Entry $304.37 to $298.28 Now $297.00 −2.42% ▼ −2.00% −1.56% vs SPY
- Oct 9, 20265w ago 8-K Neutral 2/10 Entry $283.34 to $298.50 Now $297.00 +4.82% ▲ +5.35% +6.84% vs SPY
- Sep 30, 20266w ago 8-K Neutral 4/10 Entry $271.83 to $278.51 Now $297.00 +9.26% ▲ +2.46% +0.54% vs SPY
- Sep 3, 202610w ago 144 Neutral 2/10 Entry $286.26 to $280.76 Now $297.00 +3.75% ▼ −1.92% −0.77% vs SPY
- Aug 18, 202612w ago 144 Neutral 2/10 Entry $278.50 to $279.32 Now $297.00 +6.64% ▲ +0.29% +0.50% vs SPY
- Aug 4, 202614w ago 144 Neutral 2/10 Entry $273.45 to $273.87 Now $297.00 +8.61% ▲ +0.16% +0.25% vs SPY
- Jul 9, 202618w ago 3 Neutral 2/10 Entry $293.46 to $283.82 Now $297.00 +1.21% ▼ −3.28% −2.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers